Company: STAA
Filing Date: 2025-12-02
Form Type: DFAN14A
Source: 0001213900-25-117366
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-12-02
Form: DFAN14A
Chunk 3
---
 compromised the sale process;                                  |

| ● | Stephen Farrell, STAAR’s CEO, who, having served for only a few months, stands to receive $24 million if the proposed                  
 transaction closes, and therefore, in our view, has a powerful incentive to mislead shareholders about STAAR’s business and prospects  
 to justify a sale of the Company and preserve his outsized payout (and who, like Yeu, failed to inform the full Board and shareholders 
 of interest from another prospective acquirer); and                                                                                    |

| ● | Arthur Butcher, Chair of the Board’s Compensation Committee, who, in our view, bears primary responsibility for the egregious 
 “golden parachute” compensation to STAAR’s executives that is nearly twice as high, relative to the implied equity value,     
 as the average amount paid in other M&A transactions in 2025—despite the fact that the average tenure of the STAAR executives 
 is less than two years.                                                                                                       |

Neal C. Bradsher, Founder and President of Broadwood, said:

“By agreeing to — and recklessly persisting with
— a deeply flawed transaction that has drawn overwhelming opposition from shareholders and all three major proxy advisory firms,
the Board has, in our view, demonstrated its lack of fidelity to the interests of shareholders and other stakeholders.

As STAAR’s largest shareholder, we have been urging
the Board for weeks to strengthen its composition by appointing new directors with the independence, expertise, and shareholder alignment
necessary to steward the Company responsibly and restore investor trust. The Board should surely understand that, among other things,
the credibility of this thrice-delayed vote and belatedly re-engineered sale process would benefit greatly from the oversight of new directors.
We anticipate that a refreshed Board would consider, among other matters, how to run a full, fair, independent, and open strategic alternatives
process to maximize value that is untainted by the process issues and conflicts of interest that afflicted this proposed transaction with
Alcon.

Unfortunately, the Board ignored these
calls to action, and STAAR’s future remains in the hands of the same individuals who designed and executed a flawed sale process.
Accordingly, we have been engaged in the byzantine process required by STAAR to call the Special Meeting to remove those directors who,
in our view, are most responsible for orchestrating and perpetuating this misbegotten proposed transaction. Broadwood is not seeking,
and has never sought, control of STAAR. Shareholders deserve a board that truly represents them.

We